Esperion Therapeutics (ESPR) Depreciation & Amortization (CF) (2012 - 2026)

Esperion Therapeutics has reported Depreciation & Amortization (CF) for 15 years, with the latest figure at $27000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 3.85% year-over-year to $27000.0; the trailing twelve-month figure through Mar 2026 stood at $101000.0 (up 13.48% YoY), and the FY2025 full-year result was $100000.0, up 58.73% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $27000.0, up from $21000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $153000.0 in Q1 2022, with the low at $6000.0 in Q4 2023.
• Historically, Depreciation & Amortization (CF) has averaged $53375.0 across 5 years, with a median of $27000.0 in 2024.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) tumbled 93.48% — and 2024, when it surged 350.0%.
• Esperion Therapeutics' Depreciation & Amortization (CF) stood at $92000.0 in 2022, then plunged by 93.48% to $6000.0 in 2023, then surged by 350.0% to $27000.0 in 2024, then decreased by 22.22% to $21000.0 in 2025, then gained by 28.57% to $27000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $27000.0 (Q1 2026), $21000.0 (Q4 2025), and $26000.0 (Q3 2025), per Business Quant data.